GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31

GYRE THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$6.09+0.01 (+0.16%)

Close on Oct 19, 2026

Market cap: $612.88M
P/E (TTM): –
Dividend yield: –

GYRE THERAPEUTICS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	117	106	113	102	7.34	21	–	0.01	1.02	–	–	0.28	3.63	58	98	86	25
Cost of Revenue	5.42	3.88	4.64	4.79	–	–	–	–	–	–	–	–	–	–	–	–	0.69
Gross Profit	111	102	109	97	–	–	–	–	–	–	–	–	–	–	–	–	24
Research & Development	14	12	14	17	69	53	44	21	13	12	5.96	5.27	6.56	49	95	65	40
Selling, General & Admin	86	74	76	72	–	–	–	–	–	–	–	–	–	–	–	–	–
Selling & Marketing	65	58	61	54	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	21	16	15	17	19	16	13	12	9.99	9.26	9.59	4.06	4.09	13	12	8.05	8.17
Advertising Expenses	11	11	11	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	105	90	176	88	95	78	57	34	23	21	16	9.32	11	66	107	73	65
Total Costs & Expenses	105	90	181	93	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Income	11	16	-67	9.20	-88	-57	-57	-34	-22	-20	-14	-7.51	-10	-8.14	-9.75	13	-40
Interest Expense	–	–	–	–	–	–	–	–	–	–	1.48	0.02	0.05	0.09	0.13	0.15	0.22
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	–	1.07	1.35	1.46	1.05
Other Non-Operating Income	-1.51	-1.66	-1.52	–	-0.08	-0.09	-0.04	1.65	0.00	0.09	0.13	0.58	0.52	1.04	1.22	1.31	0.83
Merger & Restructuring Charges	–	–	–	1.01	4.17	–	–	–	0	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0.00	-0.07	-0.63	0.00	–	–	–	-0.12	0.00	2.23	0	-0.08	-0.21	0.06	–	–	–
Pretax Income	14	23	-77	9.41	-88	–	–	–	–	–	–	-29	-47	-7.10	-8.53	14	-39
Income Tax Expense	4.56	5.32	8.52	5.10	–	–	–	–	–	–	–	3.48	0.01	-0.10	0	3.53	-0.09
Income from Continuing Operations	9.88	18	-85	4.31	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	9.88	18	-85	4.31	-88	-56	-55	-30	-22	–	–	–	–	–	–	–	–
Minority Interest in Earnings	4.85	5.81	7.45	2.01	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	9.88	18	-85	4.31	-88	-56	-55	-30	-22	-17	-15	-6.61	-9.97	-7.00	-8.53	11	-39
Preferred Dividends	–	–	–	–	–	–	–	–	3.95	–	–	–	–	–	–	–	–
Net Income to Common	5.03	12	-93	2.30	–	-56	-55	-30	-26	-17	–	–	–	–	–	–	–
EPS (Basic)(per share)	0.06	0.14	-1.41	0.04	-2.87	-2.93	-4.60	-2.68	-7.45	-21.75	-49.99	-269.85	-409.35	-289.80	-372.60	524.40	-2,125.20
EPS (Diluted)(per share)	0.02	0.05	-1.41	0.03	-2.87	-2.93	-4.60	-2.68	-7.45	-21.75	-49.99	-269.85	-409.35	-289.80	-372.60	496.80	-2,125.20
Shares Outstanding (Basic, Weighted)(shares)	89	85	66	64	31	19	12	11	3.42	0.78	0.30	0.02	0.02	0.02	0.02	0.02	0.02
Shares Outstanding (Diluted, Weighted)(shares)	103	102	66	76	31	19	12	11	3.42	0.78	0.30	0.02	0.02	0.02	0.02	0.02	0.02
Dividend per Share(per share)	–	–	–	1.43	–	–	–	–	–	–	–	–	–	–	–	–	–
EBITDA	14	18	-66	10	-88	-57	-57	-34	-22	-20	-13	-6.83	-9.15	-5.93	-7.27	15	-38
Net Interest Income	1.75	1.55	1.04	0.73	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 94.3%
Operating margin: -14.0%
Net margin: -23.6%
Return on equity, FY2025: 15.7%

Financial strength

Current ratio: 4.26
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 151.0%

Valuation

P/E ratio: –
Price to sales: 5.13
Price to book: 5.68
Dividend yield: –